Supriya Lifescience: PAT growth of 33% …

Jun 7, 2024

Doubling revenue to Rs 1,000 cr by FY27 at a CAGR of 21%. FY25 revenue growth to be at 20%+. Maintaining EBITDA margin of 28-30% till FY27

Comments

#nojs-banner { position: fixed; bottom: 0; left: 0; padding: 16px 16px 16px 32px; width: 100%; box-sizing: border-box; background: red; color: white; font-family: -apple-system, "Segoe UI", Roboto, Helvetica, Arial, sans-serif, "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Symbol"; font-size: 13px; line-height: 13px; } #nojs-banner a { color: inherit; text-decoration: underline; } This site requires JavaScript to run correctly. Please turn on JavaScript or unblock scripts